Zura Bio (ZURA) Net Equity Issued and Repurchased (2022 - 2025)

Zura Bio's Net Equity Issued and Repurchased history runs 4 years deep, the most recent figure standing at $7000.0 for Q4 2025.

• On a quarterly basis, Net Equity Issued and Repurchased rose 120.59% year-over-year to $7000.0 in Q4 2025; TTM through Mar 2026 was $7000.0, a 100.02% increase from a year earlier, with the FY2025 full-year figure at $5.1 million, down 7.27% from the prior year.
• Net Equity Issued and Repurchased eased to $7000.0 in Q4 2025 per ZURA's latest filing, from $5.1 million in the prior quarter.
• Across five years, Net Equity Issued and Repurchased topped out at $56.7 million in Q1 2023 and bottomed at -$49.7 million in Q3 2024.
• The 4-year median for Net Equity Issued and Repurchased is $17000.0 (2023), against an average of $3.2 million.
• Across the five-year window, Net Equity Issued and Repurchased surged 466.83% in 2023 and sank 300.0% in 2024, its largest moves.
• Year by year, Net Equity Issued and Repurchased stood at $10.0 million in 2022, then sank by 99.83% to $17000.0 in 2023, then sank by 300.0% to -$34000.0 in 2024, then soared by 120.59% to $7000.0 in 2025.
• Per Business Quant, the three latest ZURA Net Equity Issued and Repurchased figures stand at $7000.0 (Q4 2025), $5.1 million (Q1 2025), and -$34000.0 (Q4 2024).